Yue Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yue Ma has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Danbo Wang
Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China
3 shared publications Jing Liu
Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Cancer Hospital of Dalian University of Technology, Shenyang, People’s Republic of China
3 shared publicationsYang Wang
Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Cancer Hospital of Dalian University of Technology, Shenyang, People’s Republic of China
3 shared publicationsXingyu Liu
Department of General Surgery, The People’s Hospital of Liaoning Province, Shenyang, People’s Republic of China
2 shared publicationsZhuo Yang
Department of Gynecology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute , Shenyang, Liaoning 110042 , P. R. China
2 shared publicationsDanbo Wang
Cancer Hospital of China Medical University: Liaoning Cancer Institute and Hospital
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 14 May 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-63
Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements
Ovarian cancer (OC) is the most lethal gynecological malignancy worldwide, characterized by heterogeneity at the molecular, cellular and anatomical levels. Most patients are diagnosed at an advanced stage, characterized by widespread peritoneal metastasis. Despite optimal cytoreductive surgery and platinum-based chemotherapy, peritoneal spread and recurrence of OC are common, resulting in poor prognoses. The overall survival of patients with OC has not substantially improved over the past few decades, highlighting the urgent necessity of new treatment options. Unlike the classical lymphatic and hematogenous metastasis observed in other malignancies, OC primarily metastasizes through widespread peritoneal seeding. Tumor cells (the “seeds”) exhibit specific affinities for certain organ microenvironments (the “soil”), and metastatic foci can only form when there is compatibility between the “seeds” and “soil.” Recent studies have highlighted the tumor microenvironment (TME) as a critical factor influencing the interactions between the “seeds” and “soil,” with ascites and the local peritoneal microenvironment playing pivotal roles in the initiation and progression of OC. Prior to metastasis, the interplay among tumor cells, immunosuppressive cells, and stromal cells leads to the formation of an immunosuppressive pre-metastatic niche in specific sites. This includes characteristic alterations in tumor cells, recruitment and functional anomalies of immune cells, and dysregulation of stromal cell distribution and function. TME-mediated crosstalk between cancer and stromal cells drives tumor progression, therapy resistance, and metastasis. In this review, we summarize the current knowledge on the onset and metastatic progression of OC. We provide a comprehensive discussion of the characteristics and functions of TME related to OC metastasis, as well as its association with peritoneal spread. We also outline ongoing relevant clinical trials, aiming to offer new insights for identifying potential effective biomarkers and therapeutic targets in future clinical practice.
- 14 May 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-63
Top Cited PapersOpen AccessRole of tumor microenvironment in ovarian cancer metastasis and clinical advancements
Ovarian cancer (OC) is the most lethal gynecological malignancy worldwide, characterized by heterogeneity at the molecular, cellular and anatomical levels. Most patients are diagnosed at an advanced stage, characterized by widespread peritoneal metastasis. Despite optimal cytoreductive surgery and platinum-based chemotherapy, peritoneal spread and recurrence of OC are common, resulting in poor prognoses. The overall survival of patients with OC has not substantially improved over the past few decades, highlighting the urgent necessity of new treatment options. Unlike the classical lymphatic and hematogenous metastasis observed in other malignancies, OC primarily metastasizes through widespread peritoneal seeding. Tumor cells (the “seeds”) exhibit specific affinities for certain organ microenvironments (the “soil”), and metastatic foci can only form when there is compatibility between the “seeds” and “soil.” Recent studies have highlighted the tumor microenvironment (TME) as a critical factor influencing the interactions between the “seeds” and “soil,” with ascites and the local peritoneal microenvironment playing pivotal roles in the initiation and progression of OC. Prior to metastasis, the interplay among tumor cells, immunosuppressive cells, and stromal cells leads to the formation of an immunosuppressive pre-metastatic niche in specific sites. This includes characteristic alterations in tumor cells, recruitment and functional anomalies of immune cells, and dysregulation of stromal cell distribution and function. TME-mediated crosstalk between cancer and stromal cells drives tumor progression, therapy resistance, and metastasis. In this review, we summarize the current knowledge on the onset and metastatic progression of OC. We provide a comprehensive discussion of the characteristics and functions of TME related to OC metastasis, as well as its association with peritoneal spread. We also outline ongoing relevant clinical trials, aiming to offer new insights for identifying potential effective biomarkers and therapeutic targets in future clinical practice.
- 3 January 2025
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 311 (1) , 123-134
Should all cervical cancer patients with positive lymph node receive definitive radiotherapy: a population-based comparative study
Objective The optimal initial management strategy for cervical cancer with lymph node metastases (LNM) remains a topic of ongoing debate. This study aimed to explore the correlation between surgery followed by postoperative radiotherapy (PORT) and definitive radiotherapy (RT), as well as their impact on the prognosis of patients with LNM. Methods Patients with positive lymph nodes (PLNs) in 2009 FIGO stage I–III cervical cancer were selected from SEER database. Kaplan–Meier and log-rank analysis were utilized to assess survival outcomes. Cox and Interaction analyses were employed to compare the survival benefits. Results 2936 patients were included in this study. Multivariate analysis revealed the choice of primary treatment significantly impacted both cancer-specific survival (CSS) and overall survival (OS), serving as an independent prognostic factor for patients with LNM. After adjusting for imbalanced variables, surgery plus PORT exhibited significant improvements in CSS and OS in the stage I–II and PLNs ≤ 5 subgroups. However, no statistically significant difference was observed between the two treatment modalities in stage III and PLNs > 5 subgroups. Through interaction analysis, it was observed that stage I–II and PLNs ≤ 5 subgroups exhibited a significant survival benefit from surgery plus PORT. Conclusion Surgery plus PORT could lead to improved outcomes for cervical cancer in patients with stage I–II or PLNs ≤ 5. However, this approach did not apply to patients with stage III or PLNs > 5. Therefore, a comprehensive assessment of LNM and local tumor spread should guide rationalized treatment modalities when managing patients presenting LNM.
- 3 January 2025
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 311 (1) , 123-134
Should all cervical cancer patients with positive lymph node receive definitive radiotherapy: a population-based comparative study
Objective The optimal initial management strategy for cervical cancer with lymph node metastases (LNM) remains a topic of ongoing debate. This study aimed to explore the correlation between surgery followed by postoperative radiotherapy (PORT) and definitive radiotherapy (RT), as well as their impact on the prognosis of patients with LNM. Methods Patients with positive lymph nodes (PLNs) in 2009 FIGO stage I–III cervical cancer were selected from SEER database. Kaplan–Meier and log-rank analysis were utilized to assess survival outcomes. Cox and Interaction analyses were employed to compare the survival benefits. Results 2936 patients were included in this study. Multivariate analysis revealed the choice of primary treatment significantly impacted both cancer-specific survival (CSS) and overall survival (OS), serving as an independent prognostic factor for patients with LNM. After adjusting for imbalanced variables, surgery plus PORT exhibited significant improvements in CSS and OS in the stage I–II and PLNs ≤ 5 subgroups. However, no statistically significant difference was observed between the two treatment modalities in stage III and PLNs > 5 subgroups. Through interaction analysis, it was observed that stage I–II and PLNs ≤ 5 subgroups exhibited a significant survival benefit from surgery plus PORT. Conclusion Surgery plus PORT could lead to improved outcomes for cervical cancer in patients with stage I–II or PLNs ≤ 5. However, this approach did not apply to patients with stage III or PLNs > 5. Therefore, a comprehensive assessment of LNM and local tumor spread should guide rationalized treatment modalities when managing patients presenting LNM.
- Open Access
- 21 October 2024
- Published by Springer Nature in Research Square
Should All Cervical Cancer Patients with Positive Lymph Node Receive Definitive Radiotherapy: A Population-Based Comparative Study
Objective: The optimal initial treatment for lymph node metastases (LNM) cervical cancer remains a subject of controversy. This study aimed to investigate the association between surgery plus postoperative radiotherapy (PORT) and definitive radiotherapy (RT), and the prognosis of patients with LNM cervical cancer. Methods: Patients with positive lymph nodes (PLNs) in 2009 FIGO stage I-III cervical cancer were selected from SEER database. Kaplan-Meier and log-rank analysis were utilized to assess survival outcomes. Cox regression and Interaction analyses were used to compare the survival benefits. Results: 2936 patients were included in this study. Multivariate analysis revealed that the choice of primary treatment significantly influenced both cancer-specific survival (CSS) and overall survival (OS), serving as an independent prognostic factor for patients with LNM. After adjusting for imbalanced variables, surgery plus PORT significantly improved CSS and OS in the stage I-II and PLNs ≤ 5 subgroups. However, no significant difference was observed between the two treatment modalities in patients with stage III and PLNs > 5 subgroups. Through interaction analysis, it was observed that patients with stage I-II and PLNs ≤ 5 exhibited a significant survival benefit from surgery plus PORT. Conclusion: For cervical cancer patients at FIGO stage I-II or those with PLNs ≤ 5, combining surgery with PORT could lead to improved outcomes. However, this approach did not apply to those at stage III or individuals with PLNs > 5. Therefore, a comprehensive assessment of LNM and local tumor spread should guide rationalized treatment options when managing patients presenting LNM.
- 21 October 2024
- Published by Springer Nature in Research Square
Open AccessShould All Cervical Cancer Patients with Positive Lymph Node Receive Definitive Radiotherapy: A Population-Based Comparative Study
Objective: The optimal initial treatment for lymph node metastases (LNM) cervical cancer remains a subject of controversy. This study aimed to investigate the association between surgery plus postoperative radiotherapy (PORT) and definitive radiotherapy (RT), and the prognosis of patients with LNM cervical cancer. Methods: Patients with positive lymph nodes (PLNs) in 2009 FIGO stage I-III cervical cancer were selected from SEER database. Kaplan-Meier and log-rank analysis were utilized to assess survival outcomes. Cox regression and Interaction analyses were used to compare the survival benefits. Results: 2936 patients were included in this study. Multivariate analysis revealed that the choice of primary treatment significantly influenced both cancer-specific survival (CSS) and overall survival (OS), serving as an independent prognostic factor for patients with LNM. After adjusting for imbalanced variables, surgery plus PORT significantly improved CSS and OS in the stage I-II and PLNs ≤ 5 subgroups. However, no significant difference was observed between the two treatment modalities in patients with stage III and PLNs > 5 subgroups. Through interaction analysis, it was observed that patients with stage I-II and PLNs ≤ 5 exhibited a significant survival benefit from surgery plus PORT. Conclusion: For cervical cancer patients at FIGO stage I-II or those with PLNs ≤ 5, combining surgery with PORT could lead to improved outcomes. However, this approach did not apply to those at stage III or individuals with PLNs > 5. Therefore, a comprehensive assessment of LNM and local tumor spread should guide rationalized treatment options when managing patients presenting LNM.
- 3 June 2023
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 45 (1-2) , 57-68
CD48 suppresses proliferation and migration as an immune-related prognostic signature in the cervical cancer immune microenvironment
Cervical cancer (CC) is one of the most common malignant tumors in gynecology. Immunotherapy and targeted therapy are two particularly effective treatments. In this study, weighted gene co-expression network analysis and CIBERSORT algorithm that quantifies the cellular composition of immune cells were used to analyze CC expression data based on the GEO database and identify modules related to CD8 + T cells. Five candidate hub genes were identified by tumor-infiltrating immune cells estimation and Kaplan–Meier survival analysis according to CC data from the Cancer Genome Atlas. Chemotherapeutic response, methylation, and gene mutation analyses were implemented so that the five candidate hub genes identified may be the potential biomarkers and therapeutic targets which were related to T cell infiltration in CC. Moreover, the results of RT-qPCR revealed that CD48 was a tumor suppressor gene, which was negatively correlated with CC stages, lymph node metastasis, and differentiation. Furthermore, the functional study verified that the interference of CD48 was able to boost the proliferation and migration ability in vitro and the growth of transplanted tumors in vivo. Overall, we identified molecular targets related to immune infiltration and prognosis, regarded CD48 as a key molecule involved in the progression of cervical cancer, thus providing new insights into the development of molecular therapy and immunotherapeutics against cervical cancer.
- 3 June 2023
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 45 (1-2) , 57-68
CD48 suppresses proliferation and migration as an immune-related prognostic signature in the cervical cancer immune microenvironment
Cervical cancer (CC) is one of the most common malignant tumors in gynecology. Immunotherapy and targeted therapy are two particularly effective treatments. In this study, weighted gene co-expression network analysis and CIBERSORT algorithm that quantifies the cellular composition of immune cells were used to analyze CC expression data based on the GEO database and identify modules related to CD8 + T cells. Five candidate hub genes were identified by tumor-infiltrating immune cells estimation and Kaplan–Meier survival analysis according to CC data from the Cancer Genome Atlas. Chemotherapeutic response, methylation, and gene mutation analyses were implemented so that the five candidate hub genes identified may be the potential biomarkers and therapeutic targets which were related to T cell infiltration in CC. Moreover, the results of RT-qPCR revealed that CD48 was a tumor suppressor gene, which was negatively correlated with CC stages, lymph node metastasis, and differentiation. Furthermore, the functional study verified that the interference of CD48 was able to boost the proliferation and migration ability in vitro and the growth of transplanted tumors in vivo. Overall, we identified molecular targets related to immune infiltration and prognosis, regarded CD48 as a key molecule involved in the progression of cervical cancer, thus providing new insights into the development of molecular therapy and immunotherapeutics against cervical cancer.
- Open Access
- 1 January 2022
- Published by Wiley in Wireless Communications and Mobile Computing
- Vol. 2022 (1)
Optimizing the Prognostic Model of Cervical Cancer Based on Artificial Intelligence Algorithm and Data Mining Technology
With the accumulation and development of medical multimodal data as well as the breakthrough in the theory and practice of artificial neural network and deep learning algorithm, the deep integration of multimodal data and artificial intelligence based on the Internet has become an important goal of the Internet of Medical Things. The deep application of the latest technologies in the medical field, such as artificial intelligence, machine learning, multimodal data, and advanced sensors, has a profound impact on the development of medical research. Artificial intelligence can achieve low‐consumption and high‐efficiency screening of specific markers due to its powerful data integration and processing capabilities, and its advantages are fully demonstrated in the construction of disease‐related risk prediction models. In this study, multi‐type cloud data were used as research objects to explore the potential of alternative CpG sites and establish a high‐quality prognosis model of cervical cancer DNA methylation big data. 14,419 strict differentially methylated CpG sites (DMCs) were identified by ChAMP methylation analysis and presented these distributions based on different genomic regions and relation to island. Further, rbsurv and Cox regression analyses were performed to construct a prognostic model integrating these four methylated CpG sites that could adequately predict the survival of patients (AUC = 0.833, P < 0.001). The low‐ and high‐risk patient groups, divided by risk score, showed significantly different overall survival (OS) in both the training (P < 0.001) and validation datasets (P < 0.005). Moreover, the model has an independent predictive value for FIGO stage and age and is more suitable for predicting survival time in patients with histological type (SCC) and histologic grade (G2/G3). Finally, the model exhibited much higher predictive accuracy compared to other known models and the corresponding expression of genes. The proposed model provides a novel signature to predict the prognosis, which can serve as a useful guide for increasing the accuracy of predicting overall survival of cervical cancer patients.
- 1 January 2022
- Published by Wiley in Wireless Communications and Mobile Computing
- Vol. 2022 (1)
Open AccessOptimizing the Prognostic Model of Cervical Cancer Based on Artificial Intelligence Algorithm and Data Mining Technology
With the accumulation and development of medical multimodal data as well as the breakthrough in the theory and practice of artificial neural network and deep learning algorithm, the deep integration of multimodal data and artificial intelligence based on the Internet has become an important goal of the Internet of Medical Things. The deep application of the latest technologies in the medical field, such as artificial intelligence, machine learning, multimodal data, and advanced sensors, has a profound impact on the development of medical research. Artificial intelligence can achieve low‐consumption and high‐efficiency screening of specific markers due to its powerful data integration and processing capabilities, and its advantages are fully demonstrated in the construction of disease‐related risk prediction models. In this study, multi‐type cloud data were used as research objects to explore the potential of alternative CpG sites and establish a high‐quality prognosis model of cervical cancer DNA methylation big data. 14,419 strict differentially methylated CpG sites (DMCs) were identified by ChAMP methylation analysis and presented these distributions based on different genomic regions and relation to island. Further, rbsurv and Cox regression analyses were performed to construct a prognostic model integrating these four methylated CpG sites that could adequately predict the survival of patients (AUC = 0.833, P < 0.001). The low‐ and high‐risk patient groups, divided by risk score, showed significantly different overall survival (OS) in both the training (P < 0.001) and validation datasets (P < 0.005). Moreover, the model has an independent predictive value for FIGO stage and age and is more suitable for predicting survival time in patients with histological type (SCC) and histologic grade (G2/G3). Finally, the model exhibited much higher predictive accuracy compared to other known models and the corresponding expression of genes. The proposed model provides a novel signature to predict the prognosis, which can serve as a useful guide for increasing the accuracy of predicting overall survival of cervical cancer patients.
- Open Access
- 2 November 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Augmented Renal Clearance: What Have We Known and What Will We Do?
Augmented renal clearance (ARC) is a phenomenon of increased renal function in patients with risk factors. Sub-therapeutic drug concentrations and antibacterial exposure in ARC patients are the main reasons for clinical treatment failure. Decades of increased research have focused on these phenomena, but there are still some existing disputes and unresolved issues. This article reviews information on some important aspects of what we have known and provides suggestion on what we will do regarding ARC. In this article, we review the current research progress and its limitations, including clinical identification, special patients, risk factors, metabolism, animal models and clinical treatments, and provide some promising directions for further research in this area.
- 2 November 2021
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Open AccessAugmented Renal Clearance: What Have We Known and What Will We Do?
Augmented renal clearance (ARC) is a phenomenon of increased renal function in patients with risk factors. Sub-therapeutic drug concentrations and antibacterial exposure in ARC patients are the main reasons for clinical treatment failure. Decades of increased research have focused on these phenomena, but there are still some existing disputes and unresolved issues. This article reviews information on some important aspects of what we have known and provides suggestion on what we will do regarding ARC. In this article, we review the current research progress and its limitations, including clinical identification, special patients, risk factors, metabolism, animal models and clinical treatments, and provide some promising directions for further research in this area.